Summit Therapeutics Announces Pricing Of U.S. Initial Public Offering And Nasdaq Global Market Listing

Published: Mar 05, 2015

OXFORD, England--(BUSINESS WIRE)--Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces the pricing of its underwritten initial public offering of 3,450,000 American Depository Shares (“ADSs”) at a public offering price of $9.90 per ADS, before underwriting discounts and commissions. The ADSs have been approved for listing on the NASDAQ Global Market and are expected to begin trading today under the ticker symbol “SMMT”. Summit’s ordinary shares will continue to trade on the AIM market of the London Stock Exchange following the offering.

Help employers find you! Check out all the jobs and post your resume.

Back to news